SCHAUMBURG, Ill., Sept. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of adenosine injection, USP, an antiarrhythmic drug used to treat paroxysmal supraventricular tachycardia. Sagent will offer this latex-free, preservative-free adenosine product in 6 mg per 2 mL single-dose glass vials for intravenous use.
Sagent and Strides Arcolab are jointly developing, supplying and marketing more than 25 injectable products for the U.S. market.
Adenosine Injection, USP, is the generic equivalent of Astellas Pharma U.S., Inc.'s Adenocard(R), an antiarrhythmic commonly used in the treatment of paroxysmal supraventricular tachycardia, a rhythm disturbance of the heart, in critical care situations. Adenosine works by slowing the electrical conduction in the heart, slowing heart rate of normalizing heart rhythm.
The package insert, which is available at www.SagentPharma.com, contains detailed information about the indication, complete side effect profile and prescribing information.
Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.
SOURCE Sagent Pharmaceuticals, Inc.
CONTACT: investors, Ronald Pauli of Sagent, +1-847-908-1604; or media,
Rebekah Noven of WeissComm Partners, +1-312-646-6293, for Sagent
Pharmaceuticals, Inc.
Web site: http://www.SagentPharma.com/
